All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Consultant-Needed-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Advent

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine

Contact the Supplier

Lead Product(s): ChAdOx1

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: The Jenner Institute, Oxford University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 11, 2020

Details:

The Jenner Institute at the University of Oxford has agreed a contract with Advent Srl, to produce the first batch of the novel coronavirus vaccine ChAdOx1 nCoV-19 for clinical testing.